pharmaceuticals

Study Shows How Pharmaceutical Companies Maneuver To Maintain Sales, High Prices

This article is for premium subscribers. Please sign up here for a tax-deductible subscription. 

If you're a premium subscriber, sign in below. 

When a generic multiple sclerosis drug hit the U.S. market in 2015, observers expected it could push down prices in a class of drugs that has skyrocketed in recent years. 

That did not happen. 

Oregon House Health Committee Grapples with Out-of-Control Drug Costs

This article is for premium subscribers. Please sign up here for a tax-deductible subscription. 

If you're a premium subscriber, sign in below. 

The committee is considering three bills aimed at tackling one of the biggest cost drivers in medicine today -- outrageously priced biological wonder drugs. One bill would prevent health insurers from gouging consumers who need these medications. A second bill would require pharmaceuticals to report their profit information to the Oregon Health Authority. The third bill would free pharmacists to dispense FDA-approved biosimilars without special state barriers.

The out-of-control and arbitrary pricing of designer prescription drugs dominated the House Health Committee on Monday, with three bills aimed at helping consumers, the state and health insurers to address the problem.

Pages

Subscribe to pharmaceuticals